Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 9
2013 10
2014 11
2015 9
2016 12
2017 21
2018 23
2019 31
2020 20
2021 31
2022 28
2023 15
2024 28
2025 44
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trial.
Valentín López JC, Yu C, Knutson TP, Kobilka A, Lyman J, Guo S, Luo B, Munro SA, Li Y, Heer R, Gaughan L, Morris MJ, Beltran H, Ryan CJ, Antonarakis ES, Armstrong AJ, Halabi S, Dehm SM. Valentín López JC, et al. Among authors: beltran h. Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-2779. Online ahead of print. Clin Cancer Res. 2026. PMID: 41587107
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
Thienger P, Paassen I, Yao X, Rubin PD, Lehner M, Lillis N, Benjak A, Shah SR, Leung AK, de Brot S, Naveed A, Daniel B, Shi M, Tremblay J, Triscott J, Cassanmagnago GA, Bolis M, Mela L, Beltran H, Chen Y, Piscuoglio S, Yu H, Ng CKY, Quigley DA, Yauch RL, Rubin MA. Thienger P, et al. Among authors: beltran h. Cancer Res. 2026 Jan 14. doi: 10.1158/0008-5472.CAN-25-2928. Online ahead of print. Cancer Res. 2026. PMID: 41534092
NSD2 targeting reverses plasticity and drug resistance in prostate cancer.
Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Gretarsson KH, Chen X, Ouerfelli O, Socciarelli F, Frankenstein Z, Dong H, Zou M, Yuan W, Yang G, Aizenman GM, Pannellini T, Xu X, Beltran H, Chen Y, Gardner K, Robinson BD, de Bono J, Gozani O, Abate-Shen C, Rubin MA, Loda M, Sawyers CL, Califano A, Lu C, Shen MM. Li JJ, et al. Among authors: beltran h. Nature. 2026 Jan;649(8095):216-226. doi: 10.1038/s41586-025-09727-z. Epub 2025 Nov 26. Nature. 2026. PMID: 41299174 Free PMC article.
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels.
Helzer KT, Sharifi MN, Sperger JM, Chrostek MR, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause H, Schehr J, Sethakorn N, Kosoff D, Kyriakopoulos CE, Bassetti M, Blitzer G, Floberg J, Sjöström M, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Helzer KT, et al. Among authors: beltran h. Nat Commun. 2025 Oct 14;16(1):9122. doi: 10.1038/s41467-025-64153-z. Nat Commun. 2025. PMID: 41087333 Free PMC article.
271 results